Assembly Biosciences, Inc. (NASDAQ:ASMB) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Shares of Assembly Biosciences, Inc. (NASDAQ:ASMB) have received a consensus rating of “Moderate Buy” from the eight brokerages that are covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and six have assigned a buy recommendation to the company. The average twelve-month price target among brokerages that have covered the stock in the last year is $41.00.

ASMB has been the subject of a number of recent research reports. Mizuho set a $40.00 price objective on shares of Assembly Biosciences and gave the stock an “outperform” rating in a research note on Thursday, November 20th. Weiss Ratings reissued a “sell (d-)” rating on shares of Assembly Biosciences in a research report on Wednesday, January 21st. Finally, HC Wainwright reaffirmed a “buy” rating and set a $50.00 price objective on shares of Assembly Biosciences in a research report on Monday, December 22nd.

Assembly Biosciences Price Performance

Shares of Assembly Biosciences stock opened at $27.34 on Tuesday. The stock has a market cap of $432.52 million, a price-to-earnings ratio of -5.71 and a beta of 1.14. The firm’s 50-day moving average is $33.41 and its two-hundred day moving average is $28.01. Assembly Biosciences has a 1 year low of $7.75 and a 1 year high of $39.71.

Assembly Biosciences (NASDAQ:ASMB) last posted its quarterly earnings results on Monday, November 10th. The biopharmaceutical company reported ($0.72) EPS for the quarter, missing the consensus estimate of ($0.50) by ($0.22). Assembly Biosciences had a negative net margin of 103.65% and a negative return on equity of 59.01%. The business had revenue of $10.79 million during the quarter, compared to the consensus estimate of $7.46 million. On average, equities analysts expect that Assembly Biosciences will post -6.87 earnings per share for the current year.

Hedge Funds Weigh In On Assembly Biosciences

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Bank of America Corp DE lifted its holdings in shares of Assembly Biosciences by 6,382.7% during the third quarter. Bank of America Corp DE now owns 3,371 shares of the biopharmaceutical company’s stock worth $86,000 after purchasing an additional 3,319 shares during the period. Qube Research & Technologies Ltd acquired a new stake in Assembly Biosciences during the 3rd quarter valued at approximately $282,000. ADAR1 Capital Management LLC acquired a new stake in Assembly Biosciences during the 3rd quarter valued at approximately $485,000. Millennium Management LLC purchased a new stake in shares of Assembly Biosciences in the 3rd quarter valued at $553,000. Finally, Acadian Asset Management LLC increased its stake in shares of Assembly Biosciences by 42.1% in the first quarter. Acadian Asset Management LLC now owns 23,027 shares of the biopharmaceutical company’s stock worth $219,000 after acquiring an additional 6,823 shares during the period. 19.92% of the stock is owned by hedge funds and other institutional investors.

Assembly Biosciences Company Profile

Assembly Biosciences, Inc (NASDAQ: ASMB) is a clinical-stage biotechnology company dedicated to the discovery, development and commercialization of novel therapies for hepatitis B virus (HBV) and hepatitis D virus (HDV) infections. The company’s core expertise lies in small-molecule modulation of viral proteins and host-targeted pathways to achieve sustained viral suppression and potential functional cure. Assembly’s research model integrates medicinal chemistry, structural biology and translational virology to advance its pipeline from early discovery through clinical development.

The company’s lead programs include core protein allosteric modulators (CpAMs) designed to disrupt the HBV lifecycle by interfering with capsid assembly and viral DNA replication, as well as prenylation inhibitors targeting the HDV lifecycle.